Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. GOOGL
6. APGE
7. USO
8. IBM
9. HOOD
10. DFTX

Go back to Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline

Edgewise Therapeutics (EWTX) PT Raised to $52 at Wedbush

June 1, 2026 2:09 PM EDT

Wedbush analyst Laura Chico raised the price target on Edgewise Therapeutics (NASDAQ: EWTX) to $52.00 (from $46.00) while maintaining a Outperform rating.

The analyst comments "Remain Outperform rated on EWTX, new $52 target. EWTX reached a deal with Servier (not covered) to acquire all... More